Singapore markets closed

Eloxx Pharmaceuticals, Inc. (ELOX)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.8800-0.0811 (-8.44%)
At close: 03:19PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 2.77M
Enterprise value 3.75M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)6.31
Enterprise value/revenue N/A
Enterprise value/EBITDA -0.21

Trading information

Stock price history

Beta (5Y monthly) 2.76
52-week change 3-85.83%
S&P500 52-week change 323.57%
52-week high 310.9000
52-week low 30.4000
50-day moving average 30.9339
200-day moving average 32.2240

Share statistics

Avg vol (3-month) 38.38k
Avg vol (10-day) 313.47k
Shares outstanding 53.14M
Implied shares outstanding 63.14M
Float 82.78M
% held by insiders 10.41%
% held by institutions 118.50%
Shares short (29 Sept 2023) 421.48k
Short ratio (29 Sept 2023) 40.66
Short % of float (29 Sept 2023) 40.80%
Short % of shares outstanding (29 Sept 2023) 40.70%
Shares short (prior month 31 Aug 2023) 433.78k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 320 Dec 2017
Ex-dividend date 4N/A
Last split factor 21:40
Last split date 302 Dec 2022

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)30 Sept 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-73.24%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -19.24M
Net income avi to common (ttm)-20.48M
Diluted EPS (ttm)-8.8800
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)4.78M
Total cash per share (mrq)1.52
Total debt (mrq)18.72M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.24
Book value per share (mrq)-6.53

Cash flow statement

Operating cash flow (ttm)-17.99M
Levered free cash flow (ttm)-8.25M